Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on May 13, 2016 2:04pm
148 Views
Post# 24871236

RE:RE:UPDATED REPORT-Research Analyst Marcel Wijma MSc May11/16

RE:RE:UPDATED REPORT-Research Analyst Marcel Wijma MSc May11/16I've downloaded and read the Van Leeuwenhoek report. My comment on it is that it is written with excellent clarity and well laid out.

I recommend everyone download it and study it. It nothing new and nothing that BDAZ hasn't covered and explained on the science side. What it does do is bring the entire picture together from the review and summaries of all of the trial results and how they got to BETonMACE, orphan trials, other indications, patents, timelines and finances.

It also covers other drugs like CEPT inhibitors, etc.

It's a greta read.
Toinv
Bullboard Posts